Data / Research funding / Fentanyl Misuse and Addiction
Fentanyl Misuse and Addiction: 221 NIH awards ($293.4M) to 109 organizations
221 NIH awards ($293.4M) in the NIH spending category Fentanyl Misuse and Addiction, to 109 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
221 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose | NIH | National Institute on Drug Abuse | 2022 to 2024 | $11,034,562 | February 1, 2019 | July 31, 2025 | PRAVETONI, MARCO | reporter.nih.gov |
| Development of SBS-226, a MOR agonist / DOR antagonist, for OUD | NIH | National Institute on Drug Abuse | 2024 to 2025 | $7,941,988 | September 30, 2024 | August 31, 2027 | REICH, JEFFREY | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,654,182 | August 15, 2023 | July 31, 2025 | GRIECO, JOSEPH | reporter.nih.gov |
| A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,087,655 | September 1, 2023 | August 31, 2025 | LI, XINHUA | reporter.nih.gov |
| Fentalog II: Medical Consequences of Novel Fentanyl Analog Overdose Using the Toxicology Investigators Consortium (TOXIC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,080,519 | April 1, 2020 | March 31, 2030 | MANINI, ALEX FRANCIS | reporter.nih.gov |
| MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $4,710,576 | July 1, 2025 | June 30, 2027 | KUO, LAWRENCE C | reporter.nih.gov |
| Impact of a novel HIV peer navigationand overdose prevention intervention on engagement in the HIV prevention and treatment cascade. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,391,293 | September 1, 2021 | June 30, 2027 | SHERMAN, SUSAN G. | reporter.nih.gov |
| Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,337,165 | September 30, 2019 | January 31, 2027 | ZHANG, YAN | reporter.nih.gov |
| Antibody-based therapy for fentanyl-related opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $4,202,550 | September 30, 2023 | August 31, 2025 | DESAI, RAJEEV INDRAJIT | reporter.nih.gov |
| Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | NIH | National Institute on Drug Abuse | 2022 to 2023 | $4,143,992 | September 30, 2019 | August 31, 2025 | GEHLERT, DONALD R | reporter.nih.gov |
| Using SMART Design to Identify an Effective and Cost-Beneficial Approach to Preventing OUD in Justice-Involved Youth | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,080,444 | September 30, 2019 | August 31, 2024 | AHRENS, KYM R | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,680,536 | April 1, 2020 | May 31, 2029 | HUYBRECHTS, KRISTA F | reporter.nih.gov |
| Synthetics in Combination (SYNC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,536,582 | September 30, 2021 | June 30, 2026 | CICCARONE, DANIEL H | reporter.nih.gov |
| UnityPhilly Response App for Overdose Reversal: Assessing Citywide Effectiveness and Sustainability | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,424,229 | September 30, 2023 | July 31, 2028 | LANKENAU, STEPHEN E | reporter.nih.gov |
| Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials | NIH | National Institute on Drug Abuse | 2025 | $3,410,308 | September 30, 2022 | July 31, 2028 | PRAVETONI, MARCO | reporter.nih.gov |
| Evaluating the impact of fentanyl test strip use among rural and urban populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,392,442 | July 1, 2021 | April 30, 2027 | MICHAELS, NICHOLE L | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| Functional and Genomic Signatures of Escalated Fentanyl Use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,237,608 | March 15, 2021 | December 31, 2026 | TURNER, JILL R. | reporter.nih.gov |
| Discriminative Stimulus Effects of Opioid Withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,097,773 | May 1, 1995 | December 31, 2026 | FRANCE, CHARLES P | reporter.nih.gov |
| Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $3,012,228 | August 1, 2022 | August 31, 2026 | TRAYNOR, JOHN R. | reporter.nih.gov |
| Mechanisms of repeated opioid use dependent remodeling in respiratory control | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,007,583 | August 5, 2022 | May 31, 2026 | GARCIA, ALFREDO J | reporter.nih.gov |
| A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and Xylazine | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,999,483 | August 1, 2024 | July 31, 2026 | LI, XINHUA | reporter.nih.gov |
| NX90: A Treatment for Overdose Caused by High Potency Opioids | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,946,808 | September 30, 2024 | August 31, 2026 | VORONKOV, MICHAEL V. | reporter.nih.gov |
| Assessing the Reach, Effectiveness, and Implementation of Multiple Interventions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,900,711 | September 30, 2022 | July 31, 2027 | KRAL, ALEXANDER H | reporter.nih.gov |
| Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,818,821 | July 1, 2022 | December 31, 2026 | MILLER, THOMAS L. | reporter.nih.gov |
| Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,813,188 | September 10, 2022 | July 31, 2027 | YAN, BINGFANG | reporter.nih.gov |
| Mechanism and Countermeasure of Fentanyl-Induced Sudden Death | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,782,566 | January 1, 2023 | November 30, 2026 | XU, FADI | reporter.nih.gov |
| Lasting Neurological Effects of Perinatal Opioids | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,739,816 | September 30, 2022 | July 31, 2027 | LOBO, MARY KAY | reporter.nih.gov |
| Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | NIH | National Institute on Drug Abuse | 2025 | $2,694,009 | September 1, 2023 | August 31, 2028 | LEVIN, HOWARD | reporter.nih.gov |
| Development of negative allosteric modulators at the mu opioid receptor | NIH | National Institute on Drug Abuse | 2025 | $2,664,000 | September 1, 2025 | August 31, 2027 | MAJUMDAR, SUSRUTA | reporter.nih.gov |
| A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement) | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,661,063 | November 1, 2023 | September 29, 2025 | MCNEIL, RYAN | reporter.nih.gov |
| Genetic Variation in Opioid Induced Respiratory Depression in Mice | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,624,578 | April 1, 2020 | January 31, 2026 | BUBIER, JASON A | reporter.nih.gov |
| Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose | NIH | National Institute on Drug Abuse | 2025 | $2,612,736 | September 15, 2025 | July 31, 2028 | BARRETT, ANDREW | reporter.nih.gov |
| IND-enabling development of a long-duration antagonist to treat opioid overdose | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,545,988 | September 15, 2023 | February 28, 2027 | ZANA, LAWRENCE J | reporter.nih.gov |
| Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV | NIH | National Institute on Drug Abuse | 2024 | $2,460,000 | July 1, 2024 | June 30, 2028 | APPA, AYESHA A | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,360,684 | July 1, 2022 | June 30, 2027 | ROTHWELL, PATRICK | reporter.nih.gov |
| Integrative single-cell spatial transcriptomic, anatomical, and functional profiling of brain-wide ensembles engaged by opioid relapse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,359,515 | September 30, 2023 | June 30, 2028 | GOLDEN, SAM | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,301,877 | September 1, 2022 | July 31, 2027 | MORE, SWATI S | reporter.nih.gov |
| NLRP inflammasome directed activation of the innate immune system produces synaptic damage in EcoHIV infected mice self-administering fentanyl | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,296,200 | July 1, 2020 | April 30, 2026 | HAUGHEY, NORMAN J | reporter.nih.gov |
| Impact of prescription stimulants on the drug overdose epidemic | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,253,245 | May 1, 2023 | March 31, 2028 | DE NADAI, ALESSANDRO STEVENS | reporter.nih.gov |
| The Rhode Island Young Adult Prescription and Illicit Drug Study (RAPIDS): Responding to Fentanyl and Associated Harms | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,243,163 | August 15, 2019 | May 31, 2025 | MARSHALL, BRANDON DAVID LEWIS | reporter.nih.gov |
| Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,207,625 | July 1, 2022 | June 30, 2027 | ZHAN, CHANG-GUO | reporter.nih.gov |
| Endocannabinoid Targeting for Opioid Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,190,554 | July 1, 2022 | June 30, 2027 | MILNES, TALLY MARIE | reporter.nih.gov |
| Sex-specific mechanisms underlying the effects of pain on opioid seeking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,163,671 | September 15, 2022 | June 30, 2027 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Repurposing FDA-approved oxytocin to treat opioid-induced respiratory depression | NIH | National Institute on Drug Abuse | 2025 | $2,104,389 | July 1, 2025 | June 30, 2027 | MENDELOWITZ, DAVID | reporter.nih.gov |
| An ethno-epidemiological study of the implementation and effectiveness of an innovative and comprehensive response to the evolving overdose epidemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,053,558 | July 1, 2017 | May 31, 2028 | KERR, THOMAS | reporter.nih.gov |
| New psychoactive substance exposure among NYC nightclub and festival attendees | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,051,804 | August 15, 2023 | May 31, 2027 | PALAMAR, JOSEPH J | reporter.nih.gov |
| DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,025,832 | May 15, 2019 | February 28, 2025 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Mechanism and Countermeasure of Carfentanil-induced Respiratory Disorder and Death | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,953,000 | June 1, 2023 | April 30, 2027 | XU, FADI | reporter.nih.gov |
| Rapid, Instrument-free and High Sensitivity Over-the-counter Urine Fentanyl Testing | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,948,098 | April 1, 2024 | March 31, 2027 | XIA, XIAOFENG | reporter.nih.gov |
| Microglia and Opioid Withdrawal: Mechanisms of Negative Reinforcement | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,910,647 | August 1, 2021 | June 30, 2027 | NEUMAIER, JOHN F | reporter.nih.gov |
| Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,866,922 | September 30, 2023 | August 31, 2027 | WERB, DANIEL M | reporter.nih.gov |
| Characterizing brain dynamic biomarkers of fentanyl using intracranial and high-density electroencephalogram in humans | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,785,719 | August 1, 2022 | May 31, 2027 | PURDON, PATRICK L. | reporter.nih.gov |
| Mining Social Media Big Data for Toxicovigilance: Studying Substance Use via Natural Language Processing and Machine Learning Methods | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,773,166 | September 30, 2022 | July 31, 2027 | SARKER, ABEED H | reporter.nih.gov |
| Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,763,772 | September 15, 2023 | July 31, 2027 | JACKSON, GEORGE W | reporter.nih.gov |
| Rapid Assessment of Illicit Drugs in Wastewater | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,742,186 | April 1, 2020 | October 31, 2025 | ARGUN, AVNI A | reporter.nih.gov |
| Using data to drive action to reduce opioid overdoses in Seattle, WA | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,723,230 | September 30, 2022 | May 31, 2028 | BANTA-GREEN, CALEB | reporter.nih.gov |
| Methamphetamine injection, associated health risk, and causes of overdose deaths. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $1,714,422 | September 30, 2022 | July 31, 2025 | KRAL, ALEXANDER H | reporter.nih.gov |
| Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,657,541 | September 15, 2023 | November 30, 2026 | DICCIANI, NANCE KATHERINE | reporter.nih.gov |
| A Rapid, Sensitive and Instrument-free Oral Fluid Fentanyl Test | NIH | National Institute on Drug Abuse | 2025 | $1,576,513 | June 15, 2025 | May 31, 2027 | XIA, XIAOFENG | reporter.nih.gov |
| Sentanyl II: A Multi-State Analysis of Fentanyl/Analogs, Naloxone, and Clinical Features of Non-Fatal Opioid Overdose | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,549,064 | July 15, 2022 | June 30, 2024 | MERCHANT, ROLAND C | reporter.nih.gov |
| Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,511,220 | June 15, 2023 | April 30, 2028 | GIPSON-REICHARDT, CASSANDRA D | reporter.nih.gov |
| Fentanyl use during pregnancy: impact on dam, placenta, and offspring development. | NIH | National Institute on Drug Abuse | 2023 | $1,509,492 | August 1, 2023 | July 31, 2026 | RÜEDI-BETTSCHEN, DANIELA | reporter.nih.gov |
| Safety and Efficacy of High Dose Buprenorphine Induction in Fentanyl Positive Emergency Department Patients | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,484,586 | September 1, 2022 | August 31, 2025 | MANINI, ALEX FRANCIS | reporter.nih.gov |
| Establishing Oprm1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,483,529 | September 30, 2024 | May 31, 2029 | PAN, YING-XIAN | reporter.nih.gov |
| A novel opioid receptor antagonist for treating abuse and overdose | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,477,314 | April 1, 2019 | February 28, 2025 | FRANCE, CHARLES P | reporter.nih.gov |
| Assessing the role of corticostriatal circuitry in polysubstance use of fentanyl and methamphetamine using rat self-administration models | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,475,011 | June 15, 2023 | April 30, 2028 | FERGUSON, SUSAN MARIE | reporter.nih.gov |
| Molecular mechanisms and functions underlying the role of Fto in mu opioid actions | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,467,928 | July 1, 2024 | April 30, 2029 | PAN, YING-XIAN | reporter.nih.gov |
| Novel antagonists as fentanyl overdose rescue therapies | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,464,573 | August 1, 2022 | July 31, 2024 | TRAYNOR, JOHN R. | reporter.nih.gov |
| Bath Salts: abuse-related and toxic effects | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,439,490 | April 1, 2015 | March 31, 2026 | COLLINS, GREGORY THOMAS | reporter.nih.gov |
| opioid receptor activation of the carotid body mitigates OIRD by fentanyl | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,424,334 | September 15, 2024 | June 30, 2028 | PRABHAKAR, NANDURI R | reporter.nih.gov |
| Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIV | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,414,384 | August 15, 2023 | May 31, 2028 | ANDREWS, ALLISON MICHELLE | reporter.nih.gov |
| Evaluation of Drug Checking as a Novel Intervention to Address the Opioid Overdose Crisis Attributable to Fentanyl and its Analogues | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,404,636 | September 30, 2021 | January 31, 2026 | TI, LIANPING | reporter.nih.gov |
| Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,393,884 | September 15, 2022 | March 31, 2026 | TORRALVA, PHILLIP RANDOLPH | reporter.nih.gov |
| Cell type transcriptional mechanisms of polysubstance choice | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,376,550 | July 1, 2023 | May 31, 2028 | HAMILTON, PETER JAMES | reporter.nih.gov |
| Development of Agents for Synthetic Opioid Overdose | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,353,358 | September 1, 2021 | July 31, 2025 | PRISINZANO, THOMAS EDWARD | reporter.nih.gov |
| Genetic Variation of Ultra-Potent Synthetic Opioid Sensitivity in Mice | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,343,870 | July 1, 2023 | May 31, 2026 | BUBIER, JASON A | reporter.nih.gov |
| A Growing Crisis of Novel Injection-Related Wounds and Skin & Soft Tissue Infections among People Who Inject Drugs: A Community-Based, Longitudinal Investigation in North Carolina | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,332,971 | September 30, 2024 | August 31, 2028 | ZIBBELL, JON ERIC | reporter.nih.gov |
| Dissecting the shared genetic mechanisms driving fentanyl addiction, cocaine addiction, and incentive sensitization using the Collaborative Cross mouse panel | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,331,986 | June 1, 2024 | March 31, 2029 | DICKSON, PRICE EVANS | reporter.nih.gov |
| Opioid and non-opioid receptor mechanisms in neurons and glia underlying fentanyl and HIV comorbidity in the striatum | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,323,578 | June 15, 2024 | March 31, 2029 | HAUSER, KURT F | reporter.nih.gov |
| Addressing Emerging Drug Threats with InstaStrip Rapid Tests | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,284,690 | May 1, 2024 | April 30, 2028 | XIA, XIAOFENG | reporter.nih.gov |
| Gabapentinoid/opioid mixtures: abuse and toxicity | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,282,475 | April 1, 2023 | January 31, 2028 | HIRANITA, TAKATO | reporter.nih.gov |
| Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,252,839 | July 15, 2023 | May 31, 2028 | HO, MING-FEN | reporter.nih.gov |
| User-centric development of closed-loop therapy for opioid overdose | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,249,134 | September 30, 2022 | December 31, 2028 | LE, VY | reporter.nih.gov |
| Omics analysis of HIV during synthetic opioid exposure | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,220,730 | March 1, 2019 | December 31, 2025 | BLACKARD, JASON T | reporter.nih.gov |
| Efficacy and signaling modulation by targeting the sodium site at mu opioid receptor | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,185,703 | July 15, 2024 | April 30, 2029 | MAJUMDAR, SUSRUTA | reporter.nih.gov |
| Combination drug therapy to treat pain with minimal or no abuse potential and side-effects | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,138,608 | September 30, 2023 | July 31, 2028 | KECK, THOMAS MCGOWAN | reporter.nih.gov |
| Licit and Illicit Opioids: Comparative Studies in Humans | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,134,119 | July 10, 2004 | July 31, 2025 | WALSH, SHARON L. | reporter.nih.gov |
| Oxytocin Neurotransmission Overcomes Sleep Apnea-Related OIRD Hypersensitivity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,122,372 | August 1, 2024 | May 31, 2029 | TONEY, GLENN M | reporter.nih.gov |
| Treatment of Fentanyl Overdose-Induced Respiratory Failure by Low-Dose Dexmedetomidine | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,102,741 | September 20, 2020 | August 31, 2025 | HAOUZI, PHILIPPE A | reporter.nih.gov |
| Brainstem mechanisms of opioid-induced respiratory depression | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,074,376 | July 15, 2024 | April 30, 2028 | LEVITT, ERICA SAWYER | reporter.nih.gov |
| Targeting PFC interneurons for personalized treatments in OUD | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,044,536 | September 15, 2024 | July 31, 2029 | JOFFE, MAX E | reporter.nih.gov |
| Dissecting the role of dorsal hippocampus to nucleus accumbens circuits in opioid seeking behavior | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,043,032 | April 1, 2024 | January 31, 2029 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Ventral Pallidum Circuits Underlying Preclinical Models of Opioid Addiction | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,015,232 | April 1, 2023 | January 31, 2028 | MAHLER, STEPHEN VINCENT | reporter.nih.gov |
| A novel drug delivery system for the prevention and rescue of fentanyl and other opioid overdoses | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,012,500 | April 1, 2023 | February 29, 2028 | ALHAMADSHEH, MAMOUN M | reporter.nih.gov |
| Optopharmacology and Sensors for Dissecting Opioid Action In Vivo | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,005,835 | September 30, 2020 | August 31, 2025 | BRUCHAS, MICHAEL R. | reporter.nih.gov |
| Novel roles for the circadian transcription factor NPAS2 and striatal dopamine D3 receptor signaling in diurnal fentanyl craving and relapse | NIH | National Institute on Drug Abuse | 2024 to 2025 | $949,237 | July 15, 2024 | May 31, 2029 | LOGAN, RYAN W | reporter.nih.gov |
| Investigating the mechanistic consequences of fentanyl-induced hypoxia and cardiorespiratory collapse | NIH | National Institute on Drug Abuse | 2024 to 2025 | $945,597 | July 15, 2024 | May 31, 2027 | GARCIA, ALFREDO J | reporter.nih.gov |
| TMS effects on circuit plasticity and drug seeking in mice. | NIH | National Institute on Drug Abuse | 2021 to 2023 | $930,088 | February 1, 2021 | January 31, 2024 | MOUSSAWI, KHALED | reporter.nih.gov |
| Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | NIH | National Institute on Drug Abuse | 2023 | $927,319 | September 1, 2023 | August 31, 2025 | LEVIN, HOWARD | reporter.nih.gov |
| Serotonin mechanisms in fentanyl-induced respiratory depression | NIH | National Institute on Drug Abuse | 2024 to 2025 | $918,848 | June 15, 2024 | April 30, 2027 | LEVITT, ERICA SAWYER | reporter.nih.gov |
| Optimizing methadone treatment strategies for opioid use disorder in the era of fentanyl | NIH | National Institute on Drug Abuse | 2025 | $915,478 | September 1, 2025 | May 31, 2030 | BEAUDOIN, FRANCESCA | reporter.nih.gov |
| Characterizing brain dynamic biomarkers of fentanyl using intracranial and high-density electroencephalogram in humans | NIH | National Institute on Drug Abuse | 2022 to 2023 | $894,029 | August 1, 2022 | August 31, 2023 | PURDON, PATRICK L. | reporter.nih.gov |
| A Virginia Patient Engagement Resource Center to Improve Substance Abuse Treatment Interventions | NIH | National Institute on Drug Abuse | 2024 to 2025 | $891,102 | July 1, 2024 | April 30, 2029 | ZIMMERMAN, EMILY BETH | reporter.nih.gov |
| DEVELOPING GPCR MODULATORS OF SOMATOSTATIN INTERNEURONS FOR THE TREATMENT OF OPIOID USE DISORDER | NIH | National Institute on Drug Abuse | 2024 to 2025 | $858,600 | August 1, 2024 | May 31, 2029 | JOFFE, MAX E | reporter.nih.gov |
| Behavioral Pharmacology of Opioid/Xylazine Mixtures | NIH | National Institute on Drug Abuse | 2024 to 2025 | $856,055 | September 15, 2024 | July 31, 2029 | MAGUIRE, DAVID RICHARD | reporter.nih.gov |
| Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose | NIH | National Institute on Drug Abuse | 2025 | $849,872 | September 30, 2021 | November 30, 2028 | CHACKERIAN, BRYCE C | reporter.nih.gov |
| Chemical biology tools for illuminating cannabinoid signaling pathways in opioid use disorder. | NIH | National Institute on Drug Abuse | 2024 to 2025 | $842,400 | August 15, 2024 | May 31, 2029 | FRANK, JAMES ALLEN | reporter.nih.gov |
| Navigating the Fentanyl Age with Community Drug Checking | NIH | National Institute on Drug Abuse | 2022 to 2023 | $820,722 | September 1, 2022 | July 31, 2024 | GREEN, TRACI C | reporter.nih.gov |
| Together Against Overdose: community developed technology to encourage drug checking, distribution of harm reduction supplies, and linkage to services | NIH | National Institute on Drug Abuse | 2024 | $803,573 | September 30, 2024 | August 31, 2026 | ARONSON, IAN DAVID | reporter.nih.gov |
| Circuit-specific molecular mechanisms in fentanyl use and relapse | NIH | National Institute on Drug Abuse | 2022 to 2024 | $746,999 | April 1, 2020 | May 31, 2025 | FOX, MEGAN ELIZABETH | reporter.nih.gov |
| Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIV | NIH | National Institute on Drug Abuse | 2023 | $730,880 | August 15, 2023 | October 26, 2023 | ANDREWS, ALLISON MICHELLE | reporter.nih.gov |
| Explicating Vulnerability and Resilience in Opioid Self-Administration in Middle Aged Rats | NIH | National Institute on Drug Abuse | 2024 to 2025 | $715,500 | September 15, 2024 | June 30, 2029 | TAFFE, MICHAEL A. | reporter.nih.gov |
| The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid Use | NIH | National Institute on Drug Abuse | 2023 | $710,671 | June 15, 2023 | March 31, 2030 | WILLIAMS, ARTHUR R | reporter.nih.gov |
| Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl | NIH | National Institute on Drug Abuse | 2023 to 2025 | $690,000 | August 15, 2023 | June 30, 2027 | KAMPMAN, KYLE MATTHEW | reporter.nih.gov |
| Applying a multiple methods approach to examine spatial and temporal variability in a state's illicit drug market | NIH | National Institute on Drug Abuse | 2025 | $688,271 | June 1, 2025 | February 28, 2030 | HEIMER, ROBERT | reporter.nih.gov |
| Dissecting the mechanisms underlying fentanyl-induced cardiorespiratory depression | NIH | National Institute on Drug Abuse | 2025 | $671,732 | May 1, 2025 | April 30, 2028 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Development of computational and AI/ML tools to accelerate discovery of vaccines and antibodies against nitazenes and fentanyl analogs | NIH | National Institute on Drug Abuse | 2025 | $637,128 | September 1, 2025 | May 31, 2028 | PRAVETONI, MARCO | reporter.nih.gov |
| Behavioral Safety and Fentanyl Education: BSAFE | NIH | National Institute on Drug Abuse | 2025 | $629,866 | September 30, 2025 | May 31, 2030 | COFFIN, PHILLIP O | reporter.nih.gov |
| Synthetic Scavenger Medical Countermeasures for Fentanyl | NIH | National Institute on Drug Abuse | 2023 to 2024 | $628,353 | June 1, 2023 | November 30, 2025 | LIU, XIAOHE | reporter.nih.gov |
| Epigenome Editing in Opioid Action | NIH | National Institute on Drug Abuse | 2024 to 2025 | $618,000 | September 30, 2020 | August 31, 2027 | LOBO, MARY KAY | reporter.nih.gov |
| Navigating the Fentanyl Age with Community Drug Checking | NIH | National Institute on Drug Abuse | 2025 | $609,810 | September 1, 2022 | December 31, 2027 | GREEN, TRACI C | reporter.nih.gov |
| Single cell opioid (fentanyl) responses in the context of HIV | NIH | National Institute on Drug Abuse | 2025 | $587,188 | July 15, 2025 | March 31, 2030 | BLACKARD, JASON T | reporter.nih.gov |
| Building and Implementing Best Practices for Buprenorphine Initiation in the Setting of Fentanyl Use | NIH | National Institute on Drug Abuse | 2023 to 2025 | $550,712 | August 15, 2023 | July 31, 2028 | BHATRAJU, ELENORE | reporter.nih.gov |
| Investigation into nTS mu opioid receptor mechanisms contributing to fentanyl-induced cardiorespiratory depression | NIH | National Institute on Drug Abuse | 2025 | $511,146 | September 1, 2025 | August 31, 2028 | RUYLE, BRIAN C | reporter.nih.gov |
| Preparation and Investigation of Monoclonal Antibodies to Block Xylazine's Mechanism of Action and Adverse Effects | NIH | National Institute on Drug Abuse | 2025 | $506,000 | July 15, 2025 | June 30, 2027 | JANDA, KIM | reporter.nih.gov |
| Identifying optimal buprenorphine dosing for OUD treatment and prevention of overdose | NIH | National Institute on Drug Abuse | 2025 | $505,573 | July 1, 2022 | November 30, 2027 | BEAUDOIN, FRANCESCA | reporter.nih.gov |
| Commitment to Recovery: Alaska Native Community Needs for Substance Use Treatment | NIH | National Institute on Drug Abuse | 2024 to 2025 | $498,161 | August 26, 2024 | July 31, 2026 | SHANE, ALIASSA | reporter.nih.gov |
| Nucleus accumbens fast-spiking interneurons regulate opioid reward and addiction | NIH | National Institute on Drug Abuse | 2024 to 2025 | $498,000 | March 1, 2022 | February 28, 2027 | LEFEVRE, EMILIA M | reporter.nih.gov |
| Determining if Activity in Specific Lateral Habenula Output Pathways Motivates Avoidance of Synthetic Opioid Withdrawal or Cue Induced Reinstatement | NIH | National Institute on Drug Abuse | 2024 to 2025 | $497,055 | June 15, 2021 | February 28, 2027 | COFFEY, KEVIN R. | reporter.nih.gov |
| The Youth Empowerment Study (YES) | NIH | National Institute on Drug Abuse | 2024 | $497,002 | September 30, 2024 | August 31, 2026 | BAGLEY, SARAH M | reporter.nih.gov |
| Xylazine and opioid overdose mitigation therapy using decoy receptor biomimetic nanoparticles, NarcoBond platform | NIH | National Institute on Drug Abuse | 2024 | $479,731 | May 15, 2024 | April 30, 2026 | ESMAELI-AZAD, BABAK | reporter.nih.gov |
| Xylazine exposure and transitions to low-frequency injecting and injection cessation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $474,583 | August 15, 2024 | July 31, 2026 | MCNEIL, RYAN | reporter.nih.gov |
| Leveraging state drug overdose data to build a comprehensive case level national dataset to inform prevention and mitigation strategies. | NIH | National Institute on Drug Abuse | 2023 to 2024 | $469,483 | April 1, 2023 | December 31, 2025 | POST, LORI ANN | reporter.nih.gov |
| Novel Mu Opioid Receptor Modulators to Counteract Synthetic Opioids | NIH | National Institute on Drug Abuse | 2025 | $465,750 | September 1, 2025 | May 31, 2030 | PAGARE, PIYUSHA P | reporter.nih.gov |
| Cardiorespiratory Pharmacodynamics of Fentanyl-Xylazine | NIH | National Institute on Drug Abuse | 2024 to 2025 | $460,625 | June 15, 2024 | May 31, 2027 | HEERDT, PAUL MARK | reporter.nih.gov |
| Modulating the pharmacodynamics of methamphetamine and fentanyl co-use via hypocretin pathways | NIH | National Institute on Drug Abuse | 2025 | $457,701 | August 1, 2025 | April 30, 2030 | SCHMEICHEL, BROOKE E | reporter.nih.gov |
| Device-free, long-term monitoring of opioid circuit activity in individual mice exposed to fentanyl | NIH | National Institute on Drug Abuse | 2025 | $454,251 | July 15, 2025 | June 30, 2027 | CORDER, GREGORY | reporter.nih.gov |
| Airway compromise and skeletal muscle rigidity as toxicity contributors in synthetic opioid and methamphetamine co-administered rats | NIH | National Institute on Drug Abuse | 2024 to 2025 | $452,603 | September 15, 2024 | August 31, 2026 | COTTEN, JOSEPH F | reporter.nih.gov |
| Repurposing L-NAC to prevent fentanyl-induced respiratory depression | NIH | National Institute on Drug Abuse | 2023 to 2024 | $442,750 | September 1, 2023 | August 31, 2025 | LEWIS, STEPHEN JOHN | reporter.nih.gov |
| Dissecting the central and peripheral mechanisms to fentanyl induced respiratory depression | NIH | National Institute on Drug Abuse | 2023 | $442,484 | July 1, 2023 | June 30, 2024 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Assessing fentanyl test strip use accuracy and fentanyl presence in the non-heroin drug supply | NIH | National Institute on Drug Abuse | 2023 to 2024 | $441,826 | May 1, 2023 | April 30, 2026 | REED, MEGAN | reporter.nih.gov |
| Xylazine and fentanyl effects on rat breathing, metabolism, and thermoregulation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $438,695 | July 1, 2024 | June 30, 2026 | COTTEN, JOSEPH F | reporter.nih.gov |
| Negative allosteric modulation of mu opioid receptors to reverse fentanyl overdose | NIH | National Institute on Drug Abuse | 2024 to 2025 | $435,875 | September 15, 2024 | August 31, 2026 | MACKIE, KENNETH | reporter.nih.gov |
| Delineation of microRNA regulatory pathways that support fentanyl-seeking behavior | NIH | National Institute on Drug Abuse | 2024 to 2025 | $435,873 | March 15, 2024 | February 28, 2026 | DAWS, STEPHANIE | reporter.nih.gov |
| Informing national overdose prevention and treatment strategies for high-risk adolescents | NIH | National Institute on Drug Abuse | 2024 | $431,750 | September 30, 2024 | September 29, 2026 | BUSHNELL, GRETA | reporter.nih.gov |
| Examination of fentanyl-induced insensitivity to risk of punishment during decision making and the potential use of methadone and buprenorphine in attenuating risk-taking deficits | NIH | National Institute on Drug Abuse | 2022 to 2023 | $430,385 | March 1, 2022 | February 28, 2025 | ORSINI, CAITLIN ANNE | reporter.nih.gov |
| New brainstem targets for counteracting opioid induced apnea | NIH | National Institute on Drug Abuse | 2022 to 2023 | $429,000 | August 1, 2022 | July 31, 2025 | FELDMAN, JACK L | reporter.nih.gov |
| Recruiting active expiration to overcome opioid-induced persistent apnea | NIH | National Institute on Drug Abuse | 2022 to 2023 | $429,000 | July 1, 2022 | June 30, 2025 | FELDMAN, JACK L | reporter.nih.gov |
| Combining Experiments, Simulations, and AI to Interrogate the Pharmacology of Fentanyl and Nitazene Derivatives | NIH | National Institute on Drug Abuse | 2025 | $428,432 | September 1, 2025 | August 31, 2026 | SHEN, JANA | reporter.nih.gov |
| Macrocyclic Arenes as Sequestrants for Drugs of Abuse | NIH | National Institute on Drug Abuse | 2024 to 2025 | $425,976 | June 15, 2024 | May 31, 2027 | ISAACS, LYLE D | reporter.nih.gov |
| Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids | NIH | National Institute on Drug Abuse | 2023 to 2024 | $424,875 | April 1, 2023 | September 30, 2025 | SCHIEFER, ISAAC T | reporter.nih.gov |
| Counteracting cardiorespiratory and subjective effects of fentanyl-xylazine mixtures using a dual antagonist approach | NIH | National Institute on Drug Abuse | 2024 | $423,708 | September 30, 2024 | September 29, 2026 | MANVICH, DANIEL F. | reporter.nih.gov |
| Neuropeptide S Receptor 1 as a Novel Target for Reducing Opioid Self-Administration and Opioid Relapse | NIH | National Institute on Drug Abuse | 2024 | $423,500 | September 15, 2024 | August 31, 2026 | TUNSTALL, BRENDAN | reporter.nih.gov |
| Dealers, Detectives, and People Who Use Drugs: Triangulating Perspectives to Understand COVID-19’s Impact on the Rural Appalachian Drug Market and Mitigate Downstream Overdose Risk | NIH | National Institute on Drug Abuse | 2022 to 2023 | $419,872 | August 15, 2022 | July 31, 2025 | VICKERS-SMITH, RACHEL | reporter.nih.gov |
| Counterfeit Pharmaceuticals: Increased Risks in the Era of Novel Synthetic Opioids and Other Designer Drugs | NIH | National Institute on Drug Abuse | 2022 to 2023 | $415,340 | April 1, 2022 | March 31, 2025 | DANIULAITYTE, RAMINTA | reporter.nih.gov |
| A Lateral Flow Assay for Rapid Saliva Fentanyl Detection (sFENTANYL) | NIH | National Institute on Drug Abuse | 2022 to 2023 | $406,352 | September 1, 2022 | August 31, 2024 | UDDIN, MD MEZBAH | reporter.nih.gov |
| The potential benefits of autophagy activator TFEB in opioid use disorder in mice | NIH | National Institute on Drug Abuse | 2024 | $405,625 | August 15, 2024 | July 31, 2026 | LAKSHMANA, MADEPALLI KRISHNAPPA | reporter.nih.gov |
| Developmental and Serotonin 5-HT2A Receptor Effects on Fentanyl Reinforcer Value | NIH | National Institute on Drug Abuse | 2024 | $400,294 | September 15, 2024 | September 14, 2027 | GARCIA, ERIK JOSEPH | reporter.nih.gov |
| Neural exosome therapeutics for treating opioid-induced brain hypoxia injuries | NIH | National Institute on Drug Abuse | 2025 | $399,997 | August 15, 2025 | July 31, 2026 | BAKER, EMILY W | reporter.nih.gov |
| User-Centric Development of a Detection Module for a Closed-Loop Solution to Opioid Overdose | NIH | National Institute on Drug Abuse | 2025 | $399,715 | August 1, 2025 | July 31, 2027 | LE, VY | reporter.nih.gov |
| iPSC-derived human neurons and OUD medications development | NIH | National Institute on Drug Abuse | 2025 | $399,536 | March 15, 2025 | February 28, 2027 | GOMEZ-GALENO, JORGE E. | reporter.nih.gov |
| I-Corps for Novel Formulation Technology for Sustained Release Naloxone | NIH | National Institute on Drug Abuse | 2023 to 2024 | $375,000 | March 1, 2024 | September 14, 2024 | TORRES LUNA, CESAR | reporter.nih.gov |
| Cholinergic interneuron regulation of opioid-related behaviors | NIH | National Institute on Drug Abuse | 2024 | $373,181 | July 15, 2024 | June 30, 2027 | RADKE, ANNA KAY | reporter.nih.gov |
| Wearable Continuous Drug Monitoring Device for Personal Medications in Opioid Use Disorders (CDM-MOUD) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $349,474 | September 1, 2024 | August 31, 2025 | HUANG, YUE | reporter.nih.gov |
| Elucidating the role of the endogenous opioid dynorphin in reward seeking | NIH | National Institute on Drug Abuse | 2023 to 2024 | $349,250 | July 1, 2023 | November 30, 2025 | GOWRISHANKAR, RAAJARAM | reporter.nih.gov |
| Decoding Neuropeptide S Modulation of OFC-mediated Reward Seeking | NIH | National Institute on Drug Abuse | 2024 to 2025 | $349,250 | February 1, 2024 | June 30, 2026 | GIRVEN, KASEY SHEA | reporter.nih.gov |
| Aversive midbrain glutamatergic regulation of the locus coeruleus during opioid withdrawal | NIH | National Institute on Drug Abuse | 2024 | $340,000 | September 15, 2024 | August 31, 2026 | MCCALL, JORDAN G. | reporter.nih.gov |
| Nucleus accumbens fast-spiking interneurons regulate opioid reward and addiction | NIH | National Institute on Drug Abuse | 2022 to 2023 | $329,130 | March 1, 2022 | February 29, 2024 | LEFEVRE, EMILIA M | reporter.nih.gov |
| A comprehensive device integrating fentanyl test strips with sample preparation features for convenient and discreet fentanyl testing in high-risk environments | NIH | National Institute on Drug Abuse | 2025 | $305,369 | August 1, 2025 | August 31, 2026 | CHUNG, JEANIE | reporter.nih.gov |
| Tranq Burn: the acidity of xylazine and fentanyl combinations | NIH | National Institute on Drug Abuse | 2025 | $293,587 | September 1, 2025 | August 31, 2027 | CICCARONE, DANIEL H | reporter.nih.gov |
| Unraveling the Mechanisms of Opioid-Induced Airway Constriction: A Path towards Novel Therapeutics for Opioid Overdose | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | May 16, 2025 | April 30, 2028 | BURGRAFF, NICHOLAS J | reporter.nih.gov |
| Effects of Xylazine Exposure on Maternal, Perinatal and Infant outcomes | NIH | National Institute on Drug Abuse | 2025 | $246,727 | September 1, 2025 | August 31, 2027 | HULL, ILANA | reporter.nih.gov |
| Unraveling the Mechanisms of Opioid-Induced Airway Constriction: A Path towards Novel Therapeutics for Opioid Overdose | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $243,481 | April 1, 2024 | May 15, 2025 | BURGRAFF, NICHOLAS J | reporter.nih.gov |
| Restoring The Mechanical Properties of the Respiratory System as a Treatment of Fentanyl Overdose-Induced Hypoventilation using Kappa Agonists | NIH | National Institute on Drug Abuse | 2023 | $241,500 | April 1, 2022 | March 31, 2025 | HAOUZI, PHILIPPE A | reporter.nih.gov |
| Targeting the Renin System for the Treatment of Pain and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $225,065 | August 15, 2025 | July 31, 2027 | EDWARDS, SCOTT | reporter.nih.gov |
| In vivo massive parallel reporter assay to analyze the function of cis-regulatory elements and variants implicated in substance use disorders | NIH | National Institute on Drug Abuse | 2025 | $197,500 | September 1, 2025 | August 31, 2027 | TELESE, FRANCESCA | reporter.nih.gov |
| Methadone Loading Dose Initiation for Hospitalized Patients with Opioid Use Disorder Using Fentanyl | NIH | National Institute on Drug Abuse | 2025 | $194,903 | April 15, 2025 | March 31, 2030 | THAKRAR, ASHISH PRAKASH | reporter.nih.gov |
| Epidemiology of xylazine-associated health harms: a cohort study of people who have injected drugs | NIH | National Institute on Drug Abuse | 2025 | $193,854 | September 1, 2025 | August 31, 2027 | FEDER, KENNETH | reporter.nih.gov |
| Fentanyl Overdose, Anhedonia and Relapse Risk | NIH | National Institute on Drug Abuse | 2025 | $193,250 | September 15, 2025 | August 31, 2027 | BYRNES, ELIZABETH M | reporter.nih.gov |
| Differential impact of acute and chronic opioids on ocular innate immunity and infections | NIH | National Eye Institute | 2025 | $192,500 | February 1, 2025 | January 31, 2027 | KUMAR, ASHOK | reporter.nih.gov |
| Understanding the effects of gestational fentanyl exposure on external morphology, neonatal opioid withdrawal, and brain volume, morphology and neurochemistry of offspring | NIH | National Institute on Drug Abuse | 2025 | $192,500 | May 1, 2025 | April 30, 2027 | PERRINE, SHANE ALAN | reporter.nih.gov |
| Fentanyl and Xylazine Interactions: Toxicity Produced by "Tranq-Dope" | NIH | National Institute on Drug Abuse | 2025 | $189,672 | August 15, 2025 | July 31, 2027 | SMITH, MARK A | reporter.nih.gov |
| Impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala | NIH | National Institute on Drug Abuse | 2025 | $184,706 | May 1, 2025 | April 30, 2030 | DOWNS, ANTHONY M | reporter.nih.gov |
| Predicting craving and relapse using neurobehavioral markers of goals and habits in opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $159,615 | July 15, 2025 | June 30, 2027 | CECELI, AHMET OGUZ | reporter.nih.gov |
| Role of a novel dynorphinergic extended amygdala circuit in pain- and fentanyl abstinence- facilitated alcohol drinking | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $152,788 | August 1, 2024 | June 30, 2026 | CUCINELLO-RAGLAND, JESSICA | reporter.nih.gov |
| Characterization of Polysubstance Use: Combined Fentanyl and Methamphetamine | NIH | National Institute on Drug Abuse | 2023 to 2025 | $146,206 | February 1, 2023 | January 31, 2027 | DAWES, MONICA H | reporter.nih.gov |
| Developing a Gene-Based Approach for Lasting Protection from Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $143,420 | June 7, 2022 | June 6, 2025 | CLEMENZA, KELLY | reporter.nih.gov |
| Investigating anti-neuroinflammatory therapeutics for polysubstance use disorders | NIH | National Institute of General Medical Sciences | 2025 | $142,100 | September 1, 2025 | August 31, 2029 | SCHMEICHEL, BROOKE E | reporter.nih.gov |
| Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist | NIH | National Institute on Drug Abuse | 2023 to 2025 | $124,834 | August 1, 2023 | July 31, 2027 | EVANS, BRIANNA | reporter.nih.gov |
| Impact of fentanyl dependence on a parabrachio-amygdalar opioid circuit | NIH | National Institute on Drug Abuse | 2023 to 2025 | $122,271 | January 1, 2023 | August 8, 2025 | WOOLDRIDGE, LISA | reporter.nih.gov |
| Determinants of transitioning from injecting to smoking fentanyl and methamphetamine and implications for harm reduction implementation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $107,862 | September 1, 2024 | August 31, 2026 | EGER, WILLIAM HENRY | reporter.nih.gov |
| A Novel Role of Interpeduncular Nucleus GLP-1Rs in Fentanyl Reinstatement | NIH | National Institute on Drug Abuse | 2023 to 2025 | $106,144 | July 1, 2023 | August 11, 2025 | HERMAN, RACHEL JASCHIK | reporter.nih.gov |
| Adaptations following chronic opioid treatment and withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2023 | $104,266 | March 1, 2020 | March 2, 2023 | ADHIKARY, SWETA | reporter.nih.gov |
| Community and big-data system approaches to identifying and understanding the health impact of xylazine | NIH | National Institute on Drug Abuse | 2024 to 2025 | $98,512 | September 1, 2024 | August 31, 2027 | KELLY, PATRICK JOHN | reporter.nih.gov |
| Molecular and Neuroanatomical Processes of Opioid addiction | NIH | National Institute on Drug Abuse | 2023 to 2024 | $95,290 | July 1, 2023 | June 30, 2025 | O'BRIEN, CHRISTOPHER M | reporter.nih.gov |
| Impact of chronic, voluntary fentanyl intake on single-cell gene expression and brain-wide neuronal activity patterns | NIH | National Institute on Drug Abuse | 2024 to 2025 | $94,985 | August 1, 2024 | July 31, 2027 | BURKE, CASSIDY TAYLOR | reporter.nih.gov |
| Exploration of the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders | NIH | National Institute on Drug Abuse | 2024 to 2025 | $91,074 | March 1, 2024 | February 28, 2027 | SAAVEDRA, SARA | reporter.nih.gov |
| Exploring the Role of Alternatively Spliced Variants of the Mu Opioid Receptor Gene, Oprm1, in Opioid-Induced Respiratory Depression in Gene Targeted Rat Models | NIH | National Institute on Drug Abuse | 2024 to 2025 | $89,416 | July 1, 2024 | June 30, 2026 | MALIK, AYMA | reporter.nih.gov |
| Sex Differences in a Rat Model of Opioid Use disorder | NIH | National Institute on Drug Abuse | 2023 to 2024 | $81,123 | March 1, 2023 | October 31, 2024 | TOWERS, ELEANOR | reporter.nih.gov |
| Cannabidiol and buprenorphine: A poly-pharmacy approach to treat opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $78,052 | May 1, 2025 | August 30, 2026 | GALBO THOMMA, LINDSEY | reporter.nih.gov |
| Calcium Imaging of Central Amygdala Activity after Fentanyl Escalation | NIH | National Institute on Drug Abuse | 2022 to 2023 | $77,555 | July 3, 2022 | December 16, 2023 | MALONE, SAMANTHA | reporter.nih.gov |
| Reversal of ventilatory depression by drug mixtures | NIH | National Institute on Drug Abuse | 2023 to 2024 | $75,296 | January 15, 2023 | January 14, 2025 | FLYNN, SHAWN MICHAEL | reporter.nih.gov |
| NAc Circuits Underlying Opioid Taking and Seeking | NIH | National Institute on Drug Abuse | 2025 | $75,052 | September 1, 2025 | August 31, 2028 | SUTLEY-KOURY, SAMANTHA | reporter.nih.gov |
| Immunoprofiling of Opioid Use Disorder Patients to inform structure-guided design of opioid-specific monoclonal antibodies | NIH | National Institute on Drug Abuse | 2023 to 2024 | $71,186 | September 1, 2023 | August 31, 2026 | ZHANG, YUE | reporter.nih.gov |
| Behavioral Pharmacology of Injury Restricted Fentanyl Analogues. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $62,446 | December 3, 2022 | December 2, 2024 | EDWARDS, SHELLEY R | reporter.nih.gov |
| Intrinsic Efficacy as a Determinant of Opioid Effectiveness in Treatment of Pain-Depressed Behavior | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $59,013 | June 1, 2022 | August 31, 2023 | EVINGTON, EDNA J | reporter.nih.gov |
| Identifying a Novel Opioid-Specific EEG Biomarker That Can Be Targeted to Improve Patient Pain- and Opioid-Related Outcomes | NIH | National Institute on Drug Abuse | 2025 | $54,538 | September 1, 2025 | August 31, 2027 | MATHER, VU NGUYEN | reporter.nih.gov |
| Real-time imaging of opioid neuromodulation with novel genetically encoded fluorescent sensors | NIH | National Institute on Drug Abuse | 2025 | $49,538 | January 6, 2026 | January 5, 2029 | TORP, LILY | reporter.nih.gov |
| Examining the Association Between Buprenorphine Dose Trajectories and Opioid Use Disorder-Related Outcomes Among Pregnant and Postpartum Women | NIH | National Institute on Drug Abuse | 2025 | $49,538 | August 1, 2025 | July 31, 2027 | GANETSKY, VALERIE | reporter.nih.gov |
| Novel Therapeutics for Treating Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $48,974 | June 10, 2025 | June 9, 2027 | INGABIRE, DIANE | reporter.nih.gov |
| Evaluating the Multiscale Effects of Fentanyl-Induced Dependence and Abstinence within the Mouse Basolateral Amygdala | NIH | National Institute on Drug Abuse | 2025 | $45,982 | August 1, 2025 | July 31, 2028 | DESFOR, SHANE | reporter.nih.gov |
| The Impact of Perinatal Fentanyl on Dopamine Neuron Circuitry and Behavior | NIH | National Institute on Drug Abuse | 2025 | $45,678 | December 12, 2024 | December 11, 2027 | MCINERNEY, JESSICA | reporter.nih.gov |
| Opioid overdose prevention in US higher education settings: a multisite, mixed methods study of college students and institutional leaders | NIH | National Institute on Drug Abuse | 2024 | $43,920 | July 1, 2024 | June 30, 2025 | FREIBOTT, CHRISTINA ELLIOTT | reporter.nih.gov |
| Mu opioid receptor-gated roles of glutamatergic and GABAergic ventral tegmental area neurons in fentanyl reward and relapse | NIH | National Institute on Drug Abuse | 2025 | $42,762 | August 15, 2025 | August 14, 2028 | PREVOST, EMILY DANIELLE | reporter.nih.gov |
| Exploring the Applicability of Potential Negative Allosteric Modulators at the Mu Opioid Receptor | NIH | National Institute on Drug Abuse | 2023 | $31,847 | January 5, 2023 | June 30, 2023 | BOSQUEZ-BERGER, TARYN | reporter.nih.gov |
| Cannabinoid type 2 receptors as a therapeutic target for substance use disorders | NIH | National Institute on Drug Abuse | 2023 | $8,368 | February 1, 2023 | February 20, 2023 | CAREY IV, LAWRENCE MICHAEL | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Washington | Seattle, WA | 14 | $23.6 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 8 | $12.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $12.2 million | 0 | $0 |
| Washington University | Saint Louis, MO | 9 | $9.2 million | 0 | $0 |
| Clear Scientific, LLC | Cambridge, MA | 2 | $9.1 million | 0 | $0 |
| University of Chicago | Chicago, IL | 4 | $8.7 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 7 | $8.5 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 8 | $8.3 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 4 | $8.3 million | 0 | $0 |
| Sparian Biosciences, Inc. | New York City, NY | 1 | $7.9 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 4 | $6.9 million | 0 | $0 |
| Park Therapeutics, Inc. | Morristown, NJ | 1 | $6.7 million | 0 | $0 |
| Mclean Hospital | Belmont, MA | 2 | $6.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 3 | $6.3 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 3 | $5.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 5 | $5.6 million | 0 | $0 |
| Instanosis, Inc. | Milford, DE | 4 | $5.2 million | 0 | $0 |
| Lovelace Biomedical Research Institute | Albuquerque, NM | 2 | $4.7 million | 0 | $0 |
| Mebias Discovery, Inc. | Philadelphia, PA | 1 | $4.7 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 3 | $4.6 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 2 | $4.3 million | 0 | $0 |
| Yale University | New Haven, CT | 4 | $4.3 million | 0 | $0 |
| Epiodyne, Inc. | San Francisco, CA | 1 | $4.1 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 2 | $4 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 2 | $3.9 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 4 | $3.8 million | 0 | $0 |
| Brown University | Providence, RI | 4 | $3.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 1 | $3.7 million | 0 | $0 |
| Coridea, LLC | New York, NY | 2 | $3.6 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 4 | $3.5 million | 0 | $0 |
| University of British Columbia | Vancouver | 2 | $3.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 3 | $3.5 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 1 | $3.4 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 1 | $3.4 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 4 | $3.1 million | 0 | $0 |
| Eleven Therapeutics Corp | Encintias, CA | 1 | $3 million | 0 | $0 |
| Serodopa Therapeutics INC | Gainesville, FL | 1 | $2.9 million | 0 | $0 |
| Enalare Therapeutics Inc. | Princeton, NJ | 1 | $2.8 million | 0 | $0 |
| Cessation Therapeutics, LLC | San Jose, CA | 1 | $2.6 million | 0 | $0 |
| Consegna Pharma, Inc. | Pittsburgh, PA | 1 | $2.5 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $2.2 million | 0 | $0 |
| George Washington University | Washington, DC | 1 | $2.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 1 | $2.1 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 1 | $2 million | 0 | $0 |
| Seattle Inst for Biomedical/clinical Res | Seattle, WA | 1 | $1.9 million | 0 | $0 |
| Stanford University | Stanford, CA | 2 | $1.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 3 | $1.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 1 | $1.8 million | 0 | $0 |
| Base Pair Biotechnologies, Inc. | Pearland, TX | 1 | $1.8 million | 0 | $0 |
| Giner, Inc. | Newton, MA | 1 | $1.7 million | 0 | $0 |
| RTM Vital Signs, LLC | Philadelphia, PA | 1 | $1.7 million | 0 | $0 |
| Rescue Biomedical, LLC | West Lafayette, IN | 2 | $1.6 million | 0 | $0 |
| University of Mississippi Med CTR | Jackson, MS | 2 | $1.6 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 5 | $1.6 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 2 | $1.4 million | 0 | $0 |
| University of Florida | Gainesville, FL | 1 | $1.4 million | 0 | $0 |
| Torralva Medical Therapeutics, LLC | Portland, OR | 1 | $1.4 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 2 | $1.3 million | 0 | $0 |
| Marshall University Research Corporation | Huntington, WV | 1 | $1.3 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 1 | $1.3 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 2 | $1.2 million | 0 | $0 |
| Rowan University | Glassboro, NJ | 1 | $1.1 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 1 | $1.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 1 | $1 million | 0 | $0 |
| University of the Pacific | Stockton, CA | 1 | $1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 1 | $949,237 | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 2 | $946,666 | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 2 | $871,833 | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 2 | $858,000 | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 1 | $849,872 | 0 | $0 |
| Ndri-Usa, Inc. | New York, NY | 1 | $803,573 | 0 | $0 |
| New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC | New York, NY | 1 | $710,671 | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 1 | $629,866 | 0 | $0 |
| Sri International | Menlo Park, CA | 1 | $628,353 | 0 | $0 |
| East Tennessee State University | Johnson City, TN | 2 | $599,801 | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 1 | $506,000 | 0 | $0 |
| Southcentral Foundation | Anchorage, AK | 1 | $498,161 | 0 | $0 |
| Boston Medical Center | Boston, MA | 1 | $497,002 | 0 | $0 |
| Cibots, Inc. | San Diego, CA | 1 | $479,731 | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $469,483 | 0 | $0 |
| Indiana University | Bloomington, IN | 2 | $467,722 | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $442,750 | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 1 | $441,826 | 0 | $0 |
| University of Texas at Austin | Austin, TX | 1 | $430,385 | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 1 | $425,976 | 0 | $0 |
| University of Toledo Health Sci Campus | Toledo, OH | 1 | $424,875 | 0 | $0 |
| Rowan University School/osteopathic Med | Stratford, NJ | 1 | $423,708 | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 1 | $423,500 | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 1 | $415,340 | 0 | $0 |
| Florida International University | Miami, FL | 1 | $405,625 | 0 | $0 |
| University of Nebraska at Omaha | Omaha, NE | 1 | $400,294 | 0 | $0 |
| Aruna Biomedical, Inc. | Athens, GA | 1 | $399,997 | 0 | $0 |
| Chemregen INC | San Diego, CA | 1 | $399,536 | 0 | $0 |
| Wayne State University | Detroit, MI | 2 | $385,000 | 0 | $0 |
| Lynthera Corporation | Lancaster, PA | 1 | $375,000 | 0 | $0 |
| Miami University | Oxford, OH | 1 | $373,181 | 0 | $0 |
| Labsys, LLC | East Lansing, MI | 1 | $349,474 | 0 | $0 |
| Taesun, LLC | Denver, CO | 1 | $305,369 | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 1 | $249,000 | 0 | $0 |
| LSU Health Sciences Center | New Orleans, LA | 1 | $225,065 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 149 | $95,469,087 | 0 | $0 |
| 2024 | 130 | $72,802,965 | 0 | $0 |
| 2023 | 103 | $61,930,944 | 0 | $0 |
| 2022 | 60 | $46,388,678 | 0 | $0 |
| 2021 | 23 | $16,822,813 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.